Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 7/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13249970 | 0.82 | TRPV1 (0.42) | TP53LMNAMAPTMDM2ALDH1A1 | |
| SCHEMBL27013365 | 0.79 | P2RX3 (0.47) | P2RX3PARP1TNKS2PARP2HDAC1 | |
| SCHEMBL14047929 | 0.79 | PARP1 (0.44) | P2RX3PARP1TNKS2PARP2HDAC1 | |
| SCHEMBL13250468 | 0.78 | P2RX3 (0.48) | P2RX3PARP1TNKS2PARP2ACHE | |
| SCHEMBL13250059 | 0.78 | PARP1 (0.44) | P2RX3PARP1TNKS2PARP2HDAC1 | |
| SCHEMBL22410754 | 0.77 | P2RX3 (0.51) | P2RX3PARP1TNKS2PARP2HDAC1 | |
| SCHEMBL22845477 | 0.77 | P2RX3 (0.46) | P2RX3HDAC1HDAC6TP53LMNA | |
| SCHEMBL13250062 | 0.77 | KDM1A (0.43) | P2RX3PARP1TNKS2PARP2HDAC1 | |
| SCHEMBL21041597 | 0.77 | P2RX3 (0.49) | P2RX3PARP1TNKS2PARP2HDAC1 | |
| SCHEMBL13249823 | 0.76 | PARP1 (0.48) | P2RX3PARP1TNKS2PARP2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| WO-2008130581-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | P2RX3 162/4885PARP1 995/4885TNKS2 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.